Data / Drug companies / Everolimus
Everolimus: 15 companies and 81 products in the FDA NDC directory
Everolimus is listed in the FDA National Drug Code Directory by 15 companies, with 81 products in commercial distribution. 70 of the products (86.4%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, for suspension, and the newest product started marketing on August 7, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 15
- Products
- 81
- Generic (ANDA) products
- 70 (86.4%)
- Application numbers
- 18
- Routes
- Oral
- Brand names
- Yulithira, Afinitor, Torpenz, Zortress, Afinitor Disperz
- openFDA record search
- api.fda.gov
Companies that list everolimus
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Biocon Pharma Inc. | 11 | tablet; tablet, for suspension | Generic drugs (ANDA) | January 14, 2026 |
| Novartis Pharmaceuticals Corporation | 11 | tablet; tablet, for suspension | New drug applications (NDA) | August 29, 2012 |
| Hikma Pharmaceuticals USA Inc. | 8 | tablet | Generic drugs (ANDA) | November 18, 2021 |
| Natco Pharma Limited | 8 | tablet | Generic drugs (ANDA) | October 1, 2021 |
| Breckenridge Pharmaceutical, Inc. | 7 | tablet; tablet, for suspension | Generic drugs (ANDA) | January 28, 2025 |
| Ascend Laboratories, LLC | 4 | tablet | Generic drugs (ANDA) | November 27, 2021 |
| Aurobindo Pharma Limited | 4 | tablet | Generic drugs (ANDA) | February 25, 2026 |
| CivicaScript LLC | 4 | tablet | Generic drugs (ANDA) | March 5, 2021 |
| I3 Pharmaceuticals, LLC | 4 | tablet | Generic drugs (ANDA) | August 7, 2026 |
| NorthStar RxLLC | 4 | tablet | Generic drugs (ANDA) | October 1, 2024 |
| Novugen Pharma (USA) LLC | 4 | tablet | Generic drugs (ANDA) | March 30, 2026 |
| Upsher-Smith Laboratories, LLC | 4 | tablet | Generic drugs (ANDA) | October 1, 2021 |
| Amneal Pharmaceuticals NY LLC | 3 | tablet, for suspension | Generic drugs (ANDA) | January 14, 2025 |
| Ani Pharmaceuticals, Inc. | 3 | tablet, for suspension | Generic drugs (ANDA) | October 10, 2025 |
| Par Health USA, LLC | 2 | tablet | Generic drugs (ANDA) | March 31, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 66 | 81.5% |
| Tablet, for suspension | 15 | 18.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 70 | 86.4% |
| New drug applications (NDA) | 11 | 13.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Kinase Inhibitor | 81 |
| mTOR Inhibitor Immunosuppressant | 81 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.